Precision oncology has led to approved, molecularly specific, biomarker-defined indications for targeted therapies. With the number of validated drug targets increasing, testing each patient’s tumor for all markers related to all possible targeted therapies is infeasible due to limited amount of tissue usually obtained via biopsies. In addition, the current companion diagnostic approach used for most targeted therapies provides limited treatment options, with a binary “yes/no” expected response to a drug and no recommendation for which treatment, among a range of possible options, is likely to be the best option for a particular patient.